Brainstorm Cell Therapeutics (BCLI) Expected to Announce Quarterly Earnings on Tuesday

Brainstorm Cell Therapeutics (NASDAQ:BCLI) is projected to post its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect Brainstorm Cell Therapeutics to post earnings of ($0.28) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, April 7, 2026 at 3:00 PM ET.

Brainstorm Cell Therapeutics Price Performance

Brainstorm Cell Therapeutics stock opened at $0.90 on Monday. The business has a 50 day moving average price of $0.67 and a two-hundred day moving average price of $0.65. Brainstorm Cell Therapeutics has a 12 month low of $0.46 and a 12 month high of $1.92. The stock has a market cap of $9.91 million, a price-to-earnings ratio of -0.27 and a beta of 0.69.

Brainstorm Cell Therapeutics Company Profile

BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.

The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).